» Articles » PMID: 26482664

Incidence and Characteristics of Autoimmune Hepatitis

Abstract

Background And Objectives: Autoimmune hepatitis (AIH) is a progressive inflammatory liver disease of unknown etiology, with limited population-based estimates of pediatric incidence. We reported the incidence of pediatric AIH in Canada and described its clinical characteristics.

Methods: We conducted a retrospective cohort study of patients aged <18 years diagnosed with AIH between 2000-2009 at all pediatric centers in Canada.

Results: A total of 159 children with AIH (60.3% female, 13.2% type 2 AIH) were identified. Annual incidence was 0.23 per 100000 children. Median age at presentation for type 1 was 12 years (interquartile range: 11-14) versus 10 years for type 2 (interquartile range: 4.5-13) (P = .03). Fatigue (58%), jaundice (54%), and abdominal pain (49%) were the most common presenting symptoms. Serum albumin (33 vs 38 g/L; P = .03) and platelet count (187 000 vs 249 000; P <.001) were significantly lower and the international normalized ratio (1.4 vs 1.2; P <.001) was higher in cirrhotic versus noncirrhotic patients. Initial treatment included corticosteroids (80%), azathioprine (32%), and/or cyclosporine (13%). Response to treatment at 1 year was complete in 90%, and partial in 3%. 3% of patients had no response, and 3% responded and later relapsed. Nine patients underwent liver transplantation, and 4 patients died at a mean follow-up of 4 years.

Conclusions: AIH is uncommon in children and adolescents in Canada. Type 1 AIH was diagnosed 5.5 times more frequently than type 2 AIH. Most patients respond well to conventional therapy, diminishing the need for liver transplantation.

Citing Articles

Quantitative fibrosis identifies biliary tract involvement and is associated with outcomes in pediatric autoimmune liver disease.

Khendek L, Castro-Rojas C, Nelson C, Alquraish M, Karns R, Kasten J Hepatol Commun. 2024; 9(1).

PMID: 39670860 PMC: 11637754. DOI: 10.1097/HC9.0000000000000594.


Autoimmune hepatitis: Towards a personalized treatment.

Costaguta A, Costaguta G, Alvarez F World J Hepatol. 2024; 16(11):1225-1242.

PMID: 39606175 PMC: 11586748. DOI: 10.4254/wjh.v16.i11.1225.


B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes.

Costaguta G, Alvarez F JPGN Rep. 2024; 5(3):326-333.

PMID: 39149184 PMC: 11322033. DOI: 10.1002/jpr3.12098.


Good long-term outcomes of primary sclerosing cholangitis in childhood.

Jerregard Skarby A, Casswall T, Bergquist A, Lindstrom L JHEP Rep. 2024; 6(8):101123.

PMID: 39139456 PMC: 11321284. DOI: 10.1016/j.jhepr.2024.101123.


Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis.

Hahn J, Yang H, Moon J, Chang J, Lee K, Kim G EClinicalMedicine. 2023; 65:102280.

PMID: 37876996 PMC: 10590724. DOI: 10.1016/j.eclinm.2023.102280.